Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 175

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Modelling NAFLD disease burden in four Asian regions—2019‐2030

Open access
Estes, Chris, Chan, Henry L. Y., Chien, Rong N., Chuang, Wan‐Long, Fung, James, Goh, George Boon-Bee, Hu, Tsung H., Huang, Jee‐Fu, Jang, Byoung K., Jun, Dae W., Kao, Jia H., Lee, Jin‐Woo, Lin, Han‐Chieh, Razavi‐Shearer, Kathryn, Seto, Wai‐Kay, Wong, Grace L. ‐H., Wong, Vincent W. ‐S., Razavi, Homie · 2020 · Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background: Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) account for an increasing proportion of liver disease in the Asia‐Pacific region. Many areas in the region are experiencing epidemics of metabolic syndrome among rapidly ageing populations. Aims: To estimate using modelling the growth in NAFLD populations, including cases with significant fibrosis that are most likely to experience advanced liver disease and related mortality. Methods: A disease progression model was used to summarise and project fibrosis progression among the NAFLD populations of Hong Kong, Singapore, South Korea and Taiwan. For each area, changes in the adult prevalence of obesity was used to extrapolate long‐term trends in NAFLD incidence. Results: In the areas studied, prevalent NAFLD cases were projected to increase 6%‐20% during 2019‐2030, while prevalent NASH cases increase 20%‐35%. Incident cases of hepatocellular carcinoma are projected to increase by 65%‐85%, while incident decompensated cirrhosis cases increase 65%‐100% by 2030. Likewise, NAFLD‐related mortality is projected to increase between 65% and 100% from 2019 to 2030. NAFLD disease burden is expected to increase alongside rising trends in metabolic syndrome and obesity among populations in the region. This leads to more cases of advanced liver disease and associated mortality. Conclusions: Preventing the growth of diabetic and obese populations will be a key factor in reducing ongoing increases in NAFLD‐related disease burden in the Asia‐Pacific region.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apt.15673

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 175

Metadata

Authors
Estes, C., Chan, H. L. Y., Chien, R. N., Chuang, W., Fung, J., Goh, G. B.-B., Hu, T. H., Huang, J., Jang, B. K., Jun, D. W., Kao, J. H., Lee, J., Lin, H., Razavi‐Shearer, K., Seto, W., Wong, G. L. ‐., Wong, V. W. ‐., & Razavi, H.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2020-03-04
Volume
51
Issue
8
Pages
801-811
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W3009311769
Cited by
175
References
12
FWCI
15.36
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.